A5106526086- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Chronic Lymphocytic Leukemia Research
- Advanced Breast Cancer Therapies
- Viral-associated cancers and disorders
- Gender, Sexuality, and Education
- Lymphoma Diagnosis and Treatment
- Genetic Syndromes and Imprinting
- Metabolism, Diabetes, and Cancer
- Biodiesel Production and Applications
- Tumors and Oncological Cases
- BRCA gene mutations in cancer
- Hedgehog Signaling Pathway Studies
- Genetic factors in colorectal cancer
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Colorectal Cancer Surgical Treatments
Instituto do Câncer do Estado de São Paulo
2014-2024
Universidade de São Paulo
2017-2024
The energy crisis and environmental degradation are pressing challenges, intensified by popula-tion growth the excessive generation of solid waste. Converting waste into energy, especially through pyrolysis, is a viable sustainable alternative. This thermal process transforms such as banana peels used tires high-value products gas, coal oil. study aims to evaluate production pyrolytic oil from pyrolysis co-pyrolysis these ma-terials, considering different proportions temperatures, well using...
e15196 Background: Currently, there is no standard treatment for patients whose tumors progressed after 1st line gemcitabine-based regimens pancreatic adenocarcinoma (PAC). Many pre-clinical studies have shown that metformin alone, or combined with paclitaxel, may antitumor activity on PAC. We tested the combination of paclitaxel and gemcitabine-refractory Methods: Uncontrolled phase II trial, based a 2–stage Simon design, locally advanced metastatic PAC, ECOG 0-2, disease regimen. The...
In breast cancer (BC) patients, the frequency of germline BRCA mutations (gBRCA) may vary according to ethnic background, age, and family history cancer. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) is second most common somatic mutated gene in BC; however, association both genes with has not been thoroughly investigated. Thus, our aims were investigate gBRCA mutation a cohort postmenopausal Brazilian BC patients gBRCA1/BRCA2 PIK3CA mutations.Forty-nine...
BACKGROUND: The addition of antiangiogenic therapies, such as bevacizumab and aflibercept, resulted in overall survival (OS) gain for patients with metastatic colorectal (mCRC). Recently the CORRECT trial demonstrated that regorafenib, an oral multi-kinase inhibitor, also led to improved OS refractory mCRC. However, efficacy safety regorafenib has not been described our region, neither outcomes following treatment aflibercept. OBJECTIVE: To evaluate Brazilian treated well according type...
782 Background: The oral multikinase inhibitor regorafenib improves overall survival in advanced colorectal cancer (CRC). aim of this study was to investigate the safety and efficacy antiangiogenic-naïve patients with chemotherapy-refractory CRC. Methods: In single-center, single-arm, phase 2b study, received 160 mg/day for 3 weeks on/1 week off. Tumor response assessed by RECIST 1.1 tumor metabolic [ 18 F] fluorodeoxyglucose positron emission tomography (PET/CT) according European...
e16749 Background: Pancreatic cancer has the prospect of becoming second leading cause death by 2030. The NCCN Guidelines recommend genetic testing for all patients with pancreatic cancer, however, spectrum germline mutations not been extensively evaluated because recent studies have explored only a limited number genes and focused predominantly on Caucasian populations. Therefore, our objective is to evaluate frequency in unselected multiethnic population. Methods: Patients from Instituto...